Skip to main content

Tafamidis Dosage

Medically reviewed by Last updated on Sep 6, 2023.

Applies to the following strengths: meglumine 20 mg; 61 mg

Usual Adult Dose for Amyloidogenic Transthyretin Amyloidosis

Tafamidis meglumine (Vyndaqel): 80 mg orally once a day (Four 20 mg capsules/day)
Tafamidis (Vyndamax): 61 mg orally once a day (One 61 mg capsule/day)


Use: For the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended
Severe liver dysfunction: Use with caution



Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:

Missed Dose: If a dose is missed, take the dose as soon as remembered or skip the missed dose and take the next dose at the regularly scheduled time; do not double the dose


Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.